EA201291447A1 - Оптически активное производное дибензиламина и способ его получения - Google Patents
Оптически активное производное дибензиламина и способ его полученияInfo
- Publication number
- EA201291447A1 EA201291447A1 EA201291447A EA201291447A EA201291447A1 EA 201291447 A1 EA201291447 A1 EA 201291447A1 EA 201291447 A EA201291447 A EA 201291447A EA 201291447 A EA201291447 A EA 201291447A EA 201291447 A1 EA201291447 A1 EA 201291447A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- dibenzylamine
- obtaining
- optically active
- active derivative
- trifluoromethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
По существу, оптически чистая (S)-транс-{4-[({2-[({1-[3,5-бис(трифторметил)фенил]этил}{5-[2-(метилсульфонил)этокси]пиримидин-2-ил}амино)метил]-4-(трифторметил)фенил}(этил)амино)метил]циклогексил}уксусная кислота, или ее соль, или ее сольват, которая обладает воздействиями в отношении снижения количества РСSK9-белка и повышения количества LDL-рецептора.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010128585 | 2010-06-04 | ||
JP2010218299 | 2010-09-29 | ||
PCT/JP2011/062751 WO2011152508A1 (ja) | 2010-06-04 | 2011-06-03 | 光学活性ジベンジルアミン誘導体及びその製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201291447A1 true EA201291447A1 (ru) | 2013-05-30 |
EA024241B1 EA024241B1 (ru) | 2016-08-31 |
Family
ID=45066863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201291447A EA024241B1 (ru) | 2010-06-04 | 2011-06-03 | Оптически активное производное дибензиламина и способ его получения |
Country Status (18)
Country | Link |
---|---|
US (1) | US8906895B2 (ru) |
EP (1) | EP2578574B1 (ru) |
JP (1) | JP5555320B2 (ru) |
KR (2) | KR20130111512A (ru) |
CN (2) | CN104529910B (ru) |
AU (1) | AU2011259929B2 (ru) |
BR (1) | BR112012030787A2 (ru) |
CA (1) | CA2801417C (ru) |
EA (1) | EA024241B1 (ru) |
ES (1) | ES2581557T3 (ru) |
HK (1) | HK1179959A1 (ru) |
IL (1) | IL223377A (ru) |
IN (1) | IN2012CN10925A (ru) |
MX (1) | MX338024B (ru) |
PT (1) | PT2578574E (ru) |
TW (1) | TWI492749B (ru) |
WO (1) | WO2011152508A1 (ru) |
ZA (1) | ZA201209372B (ru) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9272966B2 (en) | 2010-07-22 | 2016-03-01 | Kowa Company, Ltd. | Method for preparing optically active 1-bromo-1[3,5-bis(trifluoromethyl)phenyl]ethane |
EP2626351A4 (en) * | 2010-10-04 | 2014-03-12 | Kowa Co | AGENT CAPABLE OF INHIBITING THE EXPRESSION OF LIPID METABOLISM-RELATED MRNA |
WO2013080999A1 (ja) * | 2011-11-29 | 2013-06-06 | 興和株式会社 | NPC1L1及び/又はLIPG mRNAの発現抑制剤並びに肥満症の予防及び/又は治療剤 |
JPWO2013081087A1 (ja) * | 2011-12-02 | 2015-04-27 | 興和株式会社 | 光学活性化合物の製造方法 |
JPWO2013137371A1 (ja) * | 2012-03-15 | 2015-08-03 | 興和株式会社 | 新規ピリミジン化合物及びそれらを含有する医薬 |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
BR112015026513A2 (pt) | 2013-04-17 | 2017-07-25 | Pfizer | derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares |
TW201512175A (zh) | 2013-05-31 | 2015-04-01 | Kowa Co | 具有二苄基胺構造之嘧啶化合物的新穎形態 |
EP3182971A4 (en) * | 2014-08-21 | 2018-04-25 | SRX Cardio, LLC | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity |
TWI691331B (zh) * | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
KR20170087880A (ko) * | 2014-11-28 | 2017-07-31 | 코와 가부시키가이샤 | 의약 |
JPWO2016084950A1 (ja) * | 2014-11-28 | 2017-09-07 | 興和株式会社 | 医薬組成物 |
JP2019131472A (ja) * | 2016-05-31 | 2019-08-08 | 興和株式会社 | 医薬組成物 |
MX2021008533A (es) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Inhibidores de la pcsk9 y metodos de uso de los mismos. |
EA202191890A1 (ru) | 2019-01-18 | 2022-02-03 | Астразенека Аб | Ингибиторы pcsk9 и способы их применения |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5189208A (en) | 1991-07-01 | 1993-02-23 | Ethyl Corporation | Ibuprofen resolution |
CN101679309B (zh) | 2007-04-13 | 2012-02-29 | 兴和株式会社 | 具有二苄胺结构的新型嘧啶化合物和含有该化合物的药物 |
US8673850B2 (en) | 2008-05-30 | 2014-03-18 | Institut De Recherches Cliniques De Montreal | PCSK9 inhibitors and methods of use thereof |
EP2626351A4 (en) | 2010-10-04 | 2014-03-12 | Kowa Co | AGENT CAPABLE OF INHIBITING THE EXPRESSION OF LIPID METABOLISM-RELATED MRNA |
-
2011
- 2011-06-03 TW TW100119614A patent/TWI492749B/zh not_active IP Right Cessation
- 2011-06-03 CN CN201510015412.7A patent/CN104529910B/zh not_active Expired - Fee Related
- 2011-06-03 JP JP2012518458A patent/JP5555320B2/ja not_active Expired - Fee Related
- 2011-06-03 CA CA2801417A patent/CA2801417C/en not_active Expired - Fee Related
- 2011-06-03 AU AU2011259929A patent/AU2011259929B2/en not_active Ceased
- 2011-06-03 WO PCT/JP2011/062751 patent/WO2011152508A1/ja active Application Filing
- 2011-06-03 IN IN10925CHN2012 patent/IN2012CN10925A/en unknown
- 2011-06-03 BR BR112012030787-8A patent/BR112012030787A2/pt not_active IP Right Cessation
- 2011-06-03 EA EA201291447A patent/EA024241B1/ru not_active IP Right Cessation
- 2011-06-03 CN CN201180027596.9A patent/CN102933559B/zh not_active Expired - Fee Related
- 2011-06-03 MX MX2012014149A patent/MX338024B/es active IP Right Grant
- 2011-06-03 KR KR1020137000104A patent/KR20130111512A/ko active Search and Examination
- 2011-06-03 US US13/700,849 patent/US8906895B2/en not_active Expired - Fee Related
- 2011-06-03 ES ES11789909.6T patent/ES2581557T3/es active Active
- 2011-06-03 EP EP11789909.6A patent/EP2578574B1/en not_active Not-in-force
- 2011-06-03 KR KR1020177017703A patent/KR20170078865A/ko not_active Application Discontinuation
- 2011-06-03 PT PT117899096T patent/PT2578574E/pt unknown
-
2012
- 2012-12-02 IL IL223377A patent/IL223377A/en active IP Right Grant
- 2012-12-11 ZA ZA2012/09372A patent/ZA201209372B/en unknown
-
2013
- 2013-06-19 HK HK13107169.5A patent/HK1179959A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TW201208688A (en) | 2012-03-01 |
PT2578574E (pt) | 2016-06-17 |
CA2801417C (en) | 2017-07-11 |
WO2011152508A1 (ja) | 2011-12-08 |
CN104529910B (zh) | 2017-05-10 |
IL223377A0 (en) | 2013-03-05 |
EP2578574B1 (en) | 2016-04-27 |
KR20170078865A (ko) | 2017-07-07 |
CN102933559A (zh) | 2013-02-13 |
EP2578574A1 (en) | 2013-04-10 |
TWI492749B (zh) | 2015-07-21 |
KR20130111512A (ko) | 2013-10-10 |
HK1179959A1 (zh) | 2013-10-11 |
EP2578574A4 (en) | 2013-12-04 |
BR112012030787A2 (pt) | 2020-09-01 |
JPWO2011152508A1 (ja) | 2013-08-01 |
JP5555320B2 (ja) | 2014-07-23 |
ES2581557T3 (es) | 2016-09-06 |
CA2801417A1 (en) | 2011-12-08 |
MX338024B (es) | 2016-03-31 |
CN102933559B (zh) | 2016-01-27 |
ZA201209372B (en) | 2014-02-26 |
US8906895B2 (en) | 2014-12-09 |
CN104529910A (zh) | 2015-04-22 |
EA024241B1 (ru) | 2016-08-31 |
US20130225814A1 (en) | 2013-08-29 |
AU2011259929B2 (en) | 2014-07-31 |
MX2012014149A (es) | 2013-02-27 |
IL223377A (en) | 2016-12-29 |
AU2011259929A1 (en) | 2013-01-17 |
IN2012CN10925A (ru) | 2015-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201291447A1 (ru) | Оптически активное производное дибензиламина и способ его получения | |
PE20140831A1 (es) | Nuevo derivado de 1,2,3,4-tetrahidroquinolina util para el tratamiento de diabetes | |
CY1121421T1 (el) | Φαρμακοτεχνικες μορφες | |
PE20141230A1 (es) | Inhibidor de cetp de oxazolidinona biciclico fusionado | |
PE20090815A1 (es) | Compuesto de amida | |
EA201390815A1 (ru) | Лечение jak2-опосредованных состояний | |
DK2097381T3 (da) | 4-[4-({[4-chlor-3-(trifluormethyl)phenyl)]carbamoyl}amino)-3-fluorphenoxy]-N-methylpyridin-2-carboxamidmonohydrat | |
EA200401136A1 (ru) | Предназначенная для перорального применения лекарственная форма для этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его солей | |
EA200970871A1 (ru) | Новое терапевтическое применение 4-[2-(4-метилфенилсульфанил)фенил]пиперидина | |
NO20061420L (no) | 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og | |
PE20110810A1 (es) | Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38 | |
ATE447559T1 (de) | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen | |
PE20120304A1 (es) | Derivados de 1,3-tiazolidina-2,4-diona con actividad sobre quinasas pim-1 y/o pim-2 y/o pim-3 | |
PE20140207A1 (es) | Composiciones y metodos para modular el fxr | |
NZ592258A (en) | Pesticidal (hetero) arylpyrrolidines | |
RS54445B1 (en) | 3,5-DIAMINO-6-CHLORO-N- (N- (4- (4- (2- (HEXYL (2,3,4,5,6-PENTAHYDROXYHEXYL) AMINO) ETHOXY) PHENYL) BUTYL) CARBAMIMIDOIL) PYRAZINE -2-CARBOXAMIDE | |
PE20141408A1 (es) | Aminoquinazolinas como inhibidores de quinasa | |
EA200802383A1 (ru) | Полиморфные формы n-гидрокси-3-[4-[[[2-(2-метил-1h-индол-3-ил)этил]амино]метил]фенил]-2e-2-акриламида | |
UY28468A1 (es) | Tableta que contiene el éster etílico de ácido 3-((2-((4-(hexiloxicarbonilamino-imino-metil)-fenilamino)-metil)-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propiónico o sus sales. | |
PE20140572A1 (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
CO6361988A2 (es) | Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)fenil]piperidina. | |
CL2007001692A1 (es) | Sal de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida; composicion farmaceutica, util para tratar una enfermedad que responde a una inhibicion de la actividad de cinasa de proteina. | |
PE20090243A1 (es) | Compuestos de imidazol sustituido como inhibidores de renina | |
CL2011003138A1 (es) | N-(protegido- n-(3-metoxi-5-metilpirazon-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridino-3-sulfonamida y su proceso de preparacion. | |
EA200970875A1 (ru) | Производные индолизинуксусной кислоты в качестве антагонистов crth2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AZ MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM BY KZ KG RU |